Hyloris Pharmaceuticals SA (HYL.BR)

EUR 5.83

(0.34%)

Gross Profit Summary of Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA's latest annual gross profit in 2023 was 1.99 Million EUR , down -42.39% from previous year.
Hyloris Pharmaceuticals SA's latest quarterly gross profit in 2023 FY was 1.64 Million EUR , down -42.39% from previous quarter.
Hyloris Pharmaceuticals SA reported a annual gross profit of 2.85 Million EUR in annual gross profit 2022, down -4.42% from previous year.
Hyloris Pharmaceuticals SA reported a annual gross profit of 2.98 Million EUR in annual gross profit 2021, up 9863.33% from previous year.
Hyloris Pharmaceuticals SA reported a quarterly gross profit of 1.5 Million EUR for 2023 Q3, up 169.93% from previous quarter.
Hyloris Pharmaceuticals SA reported a quarterly gross profit of 557 Thousand EUR for 2023 Q1, down -15.67% from previous quarter.

Annual Gross Profit Chart of Hyloris Pharmaceuticals SA (2023 - 2017)

Historical Annual Gross Profit of Hyloris Pharmaceuticals SA (2023 - 2017)

Year	Gross Profit	Gross Profit Growth
2023	1.99 Million EUR	-42.39%
2022	2.85 Million EUR	-4.42%
2021	2.98 Million EUR	9863.33%
2020	30 Thousand EUR	20.0%
2019	25 Thousand EUR	-3.85%
2018	26 Thousand EUR	-77.97%
2017	118 Thousand EUR	0.0%

Year	Gross Profit	Gross Profit Growth
2023 Q2	557 Thousand EUR	0.0%
2023 Q3	1.5 Million EUR	169.93%
2023 Q1	557 Thousand EUR	-15.67%
2023 FY	1.64 Million EUR	-42.39%
2023 Q4	1.5 Million EUR	0.0%
2022 Q2	971.99 Thousand EUR	100.0%
2022 FY	2.85 Million EUR	-4.42%
2022 Q4	660.5 Thousand EUR	0.0%
2022 Q3	660.5 Thousand EUR	-32.05%
2022 Q1	485.99 Thousand EUR	-77.38%
2021 FY	2.98 Million EUR	9863.33%
2021 Q4	2.14 Million EUR	95.99%
2021 Q3	1.09 Million EUR	37.75%
2021 Q2	796 Thousand EUR	100.0%
2021 Q1	398 Thousand EUR	1296.49%
2020 Q2	-70 Thousand EUR	-262.79%
2020 FY	30 Thousand EUR	20.0%
2020 Q4	28.5 Thousand EUR	0.0%
2020 Q1	43 Thousand EUR	761.54%
2020 Q3	28.5 Thousand EUR	140.71%
2019 Q2	21 Thousand EUR	23.53%
2019 Q3	-6500.00 EUR	-130.95%
2019 Q1	17 Thousand EUR	0.0%
2019 FY	25 Thousand EUR	-3.85%
2019 Q4	-6500.00 EUR	0.0%
2018 FY	26 Thousand EUR	-77.97%
2017 FY	118 Thousand EUR	0.0%

Peer Gross Profit Comparison of Hyloris Pharmaceuticals SA

Name	Gross Profit	Gross Profit Difference
Nicox S.A.	-11.5 Million EUR	117.335%
European Medical Solutions	13.51 Million EUR	85.242%
FERMENTALG	535 Thousand EUR	-272.71%
argenx SE	925.49 Million EUR	99.785%
BioSenic S.A.	543 Thousand EUR	-267.219%
Celyad Oncology SA	33 Thousand EUR	-5942.424%
Onward Medical N.V.	-14.81 Million EUR	113.457%
Oxurion NV	104 Thousand EUR	-1817.308%
PHAXIAM Therapeutics S.A.	1.32 Million EUR	-50.377%
Financière de Tubize SA	-2.02 Million EUR	198.247%
UCB SA	3.34 Billion EUR	99.94%